Effect of the cyclo-oxygenase inhibitor indobufen on platelet accumulation in prosthetic vascular grafts.
An in vivo method of measuring thrombus deposition and pseudo-intimal thickening in prosthetic arterial grafts in an animal model is described. The effect of indobufen, a new cyclo-oxygenase inhibitor, was evaluated and compared to aspirin plus dipyridamole and placebo in 24 greyhounds. Luminal platelet accumulation expressed as thrombogenicity index was 0.33 +/- 0.07 in the placebo group. This was significantly reduced to 0.14 +/- 0.01 by indobufen (P less than 0.05). The reduction to 0.19 +/- 0.04 by aspirin plus dipyridamole failed to achieve statistical significance. Pseudointimal thickness when measured 28 days after implacement was significantly reduced to 21.4 +/- 10.6 per cent by indobufen (P less than 0.01) and 29.4 +/- 10.6 per cent by aspirin plus dipyridamole (P less than 0.02) compared to 75 +/- 10 per cent found in the placebo group. This prosthetic graft model has considerable advantages in the evaluation of potential platelet inhibitory drugs for use in vascular surgery.
D000818:Animals; D001241:Aspirin / Q000627:therapeutic use; D001807:Blood Vessel Prosthesis; D004176:Dipyridamole / Q000627:therapeutic use; D004195:Disease Models, Animal; D004285:Dogs; D004341:Drug Evaluation; D006083:Graft Occlusion, Vascular / Q000517:prevention & control*; D054833:Isoindoles; D010654:Phenylbutyrates / Q000627:therapeutic use*; D010974:Platelet Aggregation / Q000187:drug effects*
D054833:Isoindoles; D010654:Phenylbutyrates; D004176:Dipyridamole; C020371:indobufen; D001241:Aspirin